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Abstract
The objective of this study was to compare letrozole-stimulated cycles to natural cycles in 208 patients undergoing
intrauterine insemination (IUI) between July of 2004 and January of 2007. Group I (n = 47) received cycle
monitoring only (natural group), Group II (n = 125) received letrozole 2.5 mg/day on cycle days three to seven,
and Group III (n = 36) received letrozole 5 mg/day on cycle days three to seven. There were no differences
between the groups in endometrial thickness or P4 on the day of hCG. Estradiol levels had higher variation in the
second half of the follicular phase in both letrozole-treated groups compared to the control group. Estradiol per
preovulatory follicle was similar in both letrozole cycles to that observed in the natural cycles. LH was lower on the
day of hCG administration in the letrozole 2.5 mg/day group vs. the natural group. In summary, letrozole results in
some minor changes in follicular, hormonal and endometrial dynamics compared to natural cycles. Increased
folliculogenesis and pregnancy rates were observed in the letrozole-treated groups compared to the natural group.
These findings need to be confirmed in larger, prospective studies.
Background
For over 40 years, the first-line therapy for ovulation
induction (OI) has been clomiphene citrate (CC) [1]. Its
inherent properties such as low price, oral route of
administration and high ovulation success rate (60-90%)
make it an attractive therapy. However, the pregnancy
rate is [2] disappointing. Sub-optimal pregnancy rates
with CC have been attributed to peripheral anti-estro-
genic effects, mainly on the endometrium and the cervi-
cal mucus[3] Gonadotropins are more effective in
ovulation induction and are associated with higher preg-
nancy rates than CC, but are expensive and carry higher
risk for ovarian hyperstimulation syndrome and multiple
gestations [4].
Newer options for ovulation induction are the third-
generation aromatase inhibitors (AIs), the most com-
monly used being letrozole. Initially introduced to treat
postmenopausal breast cancer, AIs are now also being
used for ovulation induction or enhancement. A recent
meta-analysis addressing the use of letrozole in assisted
conception concluded that letrozole is as effective as
other methods of ovulation induction [5]. When letro-
zole is used in combination with gonadotropins, it leads
to lower gonadotropin requirements and pregnancy
rates similar to gonadotropin treatment alone [6]. In a
study comparing combined therapy of letrozole (2.5 mg/
day or 5.0 mg/day) and recombinant FSH with recombi-
nant FSH alone in an intrauterine insemination (IUI)
program, 5 mg/day of letrozole was more cost-effective
than the 2.5 mg/day in co-treatment with no adverse
effect on pregnancy rate or outcome [7].
Aromatase inhibitors for ovulation induction are orally
administered, and are relatively inexpensive with minor
side effects such as very infrequent headaches and leg
cramps[8]. Aromatase inhibitors increase endogenous
FSH production in response to decreased estrogen bio-
synthesis in the ovary and extraovarian tissues, including
t h eb r a i n[ 9 ] .B e c a u s et h e yd on o td e p l e t ee s t r o g e n
receptors like CC, normal central feedback mechanisms
remain intact[10]. As the dominant follicle grows and
* Correspondence: casper@lunenfeld.ca
3Reproductive Sciences Division, Department of Obstetrics and Gynecology,
University of Toronto, Toronto, Canada
Full list of author information is available at the end of the article
Bedaiwy et al. Reproductive Biology and Endocrinology 2011, 9:83
http://www.rbej.com/content/9/1/83
© 2011 Bedaiwy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.estrogen levels rise, normal negative feedback occurs
centrally resulting in suppression of FSH and atresia of
the smaller growing follicles. Therefore, a single domi-
nant follicle, and mono-ovulation, is the rule in most
cases[11] with the clear advantage of reducing multiple-
gestation pregnancies.
Compared to CC, letrozole has been associated with
lower preovulatory estradiol (E2) levels [12], as well as
thicker endometrium and a trend towards higher pregnancy
rates[13]. Standard ovarian stimulation protocols often pro-
duce high preovulatory E2 levels that could adversely affect
the development of the endometrium, the follicles, and the
embryo. Therefore, the lower E2 when using AIs may lead
to an improvement of implantation [14,15].
There have been several studies comparing letrozole
to CC. However, there is a paucity of research compar-
ing letrozole with natural cycles. Larger studies compar-
ing CC, letrozole, and natural cycles in a single study
are necessary to further characterize the effect of letro-
zole on hormonal dynamics and pregnancy rates. Our
hypothesis is that letrozole-treated cycles mimic natural
cycles in hormonal and endometrial parameters. The
aim of this study was to compare cycle dynamics in
letrozole-treated versus natural cycles in infertile
patients undergoing intrauterine insemination (IUI).
Methods
Patient recruitment and counseling
We conducted a retrospective cohort study of 208 con-
secutive infertile patients who were recruited to partici-
pate. Briefly, patients underwent IUI between July of
2004 and January of 2007 at the Toronto Center For
Assisted Reproductive Technology, Toronto, Canada.
Patients were divided into three groups. The first group
(n = 47) received cycle monitoring only (natural cycle;
group I). The 2 remaining groups received letrozole on
cycle days three to seven at either 2.5 mg/day (n = 125)
(group II) or 5 mg/day (n = 36) (group III). An
informed consent was obtained from all participants
clearly denoting the off-label use of the medication prior
to treatment. Subsequently IRB approval was obtained
to use their data for the purposes of this study.
Causative factors of infertility were investigated and
defined as follows. Tubal patency was confirmed by sono-
hysterography with contrast, hysterosalpingography, and
or pelvic laparoscopy. Mild male factor infertility was diag-
nosed according to the World Health Organization
(WHO) criteria for normal semen[16]. Endometriosis was
diagnosed by pelvic laparoscopy. Unexplained infertility
was based on the exclusion of known factors of infertility.
Cycle monitoring and insemination
All patients were followed with serial measurements of
serum estradiol (E2), progesterone (P4), and luteinizing
h o r m o n e( L H )u s i n gar a d i o i m m u n o a s s a y( R I A )k i t .
Transvaginal ultrasonography (TVS) was performed for
follicular diameter tracking and measurement of endo-
metrial thickness. We measured follicular diameter in 2
perpendicular planes and calculated the mean, while
endometrial thickness was measured in the sagittal
plane at the widest part of endometrial cavity. Serum
samples were obtained and TVS performed on cycle
days three, seven, once between days 9 and 11, the day
of human chorionic gonadotropin (hCG) administration,
and when a follicle achieved a diameter of ≥16 mm.
Serum follicle stimulating hormone (FSH) was measured
on day 3 only. The results for E2 and P4 levels were
reported as picomoles per liter and nanomoles per liter,
respectively, and LH and FSH levels were reported in
international units per liter.
An LH surge was defined as an increase in LH level
greater than 100% over the mean of the preceding 2
measures. IUI was performed 36-40 hours after hCG
administration if no endogenous LH surge occurred. If
an endogenous LH surge was detected on the day of
hCG administration, two IUIs were performed at 24
and 48 h. Pregnancy was diagnosed by quantitative b-
hCG assay two weeks after the insemination. Clinical
pregnancy was confirmed by observing fetal cardiac
pulsation four weeks after positive pregnancy test by
TVS.
Outcome parameters
Hormonal outcome measures were E2,P 4,L Ha n dF S H .
Non-hormonal outcomes were number and size of
growing follicles, endometrial thickness, and pregnancy.
All three treatment groups were compared to each
other for hormonal, endometrial and follicular dynamics,
while the two groups receiving letrozole were combined
for comparison against the natural cycle group for preg-
nancy rates.
Statistical analysis
Data management was done using a preprepared Excel
data spreadsheet. Outcome measures are expressed as
mean ± standard deviation from the mean (SD). Statisti-
cal significance for continuous variables was calculated
using ANOVA test. Categorical variables were compared
using the c
2 and Fisher’s Exact Test. P < 0.05 was consid-
ered statistically significant. Statistical analysis was per-
formed with SPSS (Release 14.01, SPSS Inc., Chicago, IL).
Results
Patients
The study included 208 patients who underwent a total
of 300 consecutive IUI cycles. There were 71 cycles in
the natural cycle group, 179 cycles in the letrozole 2.5
mg/day group, and 50 cycles in the letrozole 5 mg/day
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Page 2 of 6group (table 1). Male factor and unexplained infertility
were the most common indications for IUI. Other iden-
tified causes of infertility included endometriosis, and
polycystic ovarian syndrome. The most frequent cause
of cycle cancellation differed among the patient groups.
T h em o s tc o m m o nc a u s eo fc a n c e l l a t i o ni nt h en a t u r a l
cycle group was anovulation, while in the letrozole 2.5
mg/day group, the main cause was presence of ovarian
cysts on cycle day 3 before the start of stimulation. The
most common cause of cancellation in the letrozole 5
mg/day group was an elevated serum FSH on cycle day
3 before the start of stimulation.
Hormonal dynamics
Values for E2,P 4 and LH are shown in table 2. The letro-
zole 5 mg/day group had significantly lower E2 on day
seven, but significantly higher E2 on the day of hCG
administration when compared to the natural group (P =
0.025 and 0.041, respectively). However, the E2 per preo-
vulatory follicle was similar in all three groups on the day
of hCG. On days 9 to 11 and the day of hCG administra-
tion, E2 had a larger variability, as evidenced by larger
standard deviations, in the letrozole groups compared to
the natural group (Table 2). LH was significantly lower on
the day of hCG administration in the letrozole 2.5 mg/day
Table 1 Study demographics
Group I (Natural cycle) Group II (letrozole 2.5 mg) Group III (letrozole 5 mg) P value
Total No of patients 47 125 36
Age (Mean ± SD) 34.8 ± 5.03 33.5 ± 4.02 33.88 ± 3.45 NS
Day 3 FSH (IU/L) 6.01 ± 1.71 6.47 ± 2.16 7.49 ± 3.76 I Vs II: 0.233
I Vs III: 0.033
Total No of cycles started 71 179 50
Completed cycle: No, [%] 63 [88.7] 142 [79.3] 43 [86]
Total number of cycles cancelled: No, [%] 8 [11.3] 37 [20.7] 7 [14] 0,06
No of monitoring visits (Mean ±SD) 2.08 ± 1.02 2.3 ± 1.12 2.68 ± 1.11 I Vs II: 0.232
I Vs III: 0.003
Causes of cycle cancelling
Poor responder: No, [%] 5 [62.5] 9 [24.3] 0 [0] NS
Ovarian cyst: No, [%] 0 [0] 16 [43.2] 2 [28.6] NS
Patient request: No, [%] 1 [12.5] 8 [21.6] 0 [0] NS
Elevated FSH: No, [%] 0 [0] 2 [5.4] 3 [42.9] NS
Others: No, [%] 2 [25] 2 [5.4] 2 [28.6] NS
Indication for IUI
Male factor infertility: No, [%] 38/71 [53.5] 55/179 [30.7] 19/50 [38] NS
Unexplained infertility: No, [%] 33/71 [46.5] 106/179 [59.3] 30/50 [60] NS
Endometriosis: No, [%] 0 [0] 9/179 [5] 0 [0] NS
Others No, [%] 1/71 [1.4] 9/179 [5] 1 [2] NS
Table 2 Hormonal dynamics: follicular phase levels of serum estradiol, progesterone, and LH
Estradiol (pmol/mL) Progesterone (pmol/mL) LH (IU/L)
Group I
(Natural
cycle)
Group II
letrozole 2.5
mg
Group III
(letrozole 5
mg)
Group I
(Natural
cycle)
Group II
(letrozole 2.5
mg
Group III
(letrozole 5
mg)
Group I
(Natural
cycle)
Group II
(letrozole 2.5
mg
Group III
(letrozole 5
mg)
D3 139.8 ±
66.36
154.22 ±
131.31
126.71 ±
46.75
2.35 ± 0.84 2.57 ±.90 2.55 ±.89 5.18 ± 2.25 5.22 ± 3.41 5.28 ± 2.71
D7 257.75 ±
187.8
196.60 ±
127.07
147.63 ±
69.74
2.08 ± 0.40 2.37 ± 0.87 2.80 ± 0.82 5.1 ± 1.34 6.71 ± 4.23 8.28 ± 4.07
D 9-11 380.48 ±
238.78
810.05 ±
178.26
562.53 ±
137.51
2.35 ± 0.85 2.2 ± 0.79 2.67 ± 0.47 5.89 ± 2.96 5.76 ± 3.30 6.65 ± 2.95
D hCG 911.48 ±
941.96
1275.41 ±
927.66
1066.16 ±
1876.37
2.46 ± 1.32 2.40 ± 0.89 2.75 ± 0.75 17.39 ±
16.09
8.92 ± 9.86 10.50 ± 13.81
E2/follicle
≥ 16 mm
593.12 ±
577.4
584.41 ±
1147.84
389.8 ±
849.79
P value: 0.025: day7 for serum Estradiol between group I and III.
P value: 0.041 day of hCG For serum Estradiol between group I and III.
P value: 0.000 LH at day of HCG group I vs II
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Page 3 of 6group compared to the natural group (p = 0.000). P4
showed no differences between any treatment groups.
Follicular dynamics
There were no statistically significant differences in folli-
cular diameter between the three groups until cycle day
seven (table 3).Compared to the natural group, both the
letrozole 2.5 mg/day and 5 mg/day groups had signifi-
cantly more follicles ≥ 10 mm on day 7 (p = 0.0001 and
0.0001, respectively), more follicles ≥ 12 mm on days 9-
11 (p = 0.0001 and 0.005), and more follicles ≥ 15 mm
on the day of hCG administration (p = 0.0001 and
0.0001).
Endometrial dynamics
When comparing endometrial thickness, neither letro-
zole group differed significantly from the natural group
on any day (table 4).
Pregnancy rate
Three out of 63 natural cycles (4.8%) and 22 out of 185
letrozole cycles (12%) resulted in pregnancy (table 5).
This difference was statistically significant (p = = 0.02).
Although only a small number of cycles were repeated
as part of this study, the cumulative pregnancy rate was
13.7% in the letrozole groups, significantly higher than
the natural group rate of 6.4% (p = 0.01). There were 3
twin pregnancies in the 2 letrozole groups and none in
the natural cycle group.
Discussion
Endometrial sparing, increased folliculogenesis, and an
increase in pregnancy rate were observed in our
letrozole-treated patients as compared to naturally-
cycling patients. The endometrial-sparing effect of letro-
zole is well-demonstrated in this study by the lack of
significant difference in endometrial thickness compared
to the natural cycle group, and also has been confirmed
by previous studies [17,18]. In addition, our ovulation
monitoring findings agree with a previous study showing
multifollicular development and better pregnancy out-
comes with the use of letrozole 5 mg/day [14,17]. Our
finding that serial serum progesterone levels were com-
parable between the three groups agrees with a previous
study [18], and suggests that letrozole does not have a
premature luteinizing effect on the developing follicle.
Table 6 summarizes the resul t so fs o m et r i a l su s i n g
letrozole as an ovulation inducing agent in different
clinical scenaria with different results and conclusions.
Although basal LH levels were comparable among the
3 groups, there was a trend towards higher LH
(although non-significant) on day 7 in the letrozole
groups. This rise might be due to the release of the
anterior pituitary from the negative feedback of E2.
Three important observations deserve mentioning. First,
the increase in LH is still well-below the levels for defi-
nition of premature LH surge. Second, after discontinua-
tion of letrozole (days 9-11), serum LH returned to
levels similar to the non-stimulated group reflecting the
short half life of the letrozole. Thirdly, a natural LH
surge was observed more frequently in non-stimulated
cycles than in the letrozole stimulated cycles. This find-
i n gi sl i k e l ya r t i f a c t u a ls i n c ew es u g g e s th C G
Table 3 Follicular dynamics in study groups
Group I Group II Group III P value
Day 3 diameter of follicles in cm 0.56 ± 1.02 0.79 ± 1.12 0.53 ± 0.86 I vs III: 0.9
I vsII: 0.26
Number of D 7-8 follicles ≥ 10 mm 0.80 ± 0.63 2.52 ± 1.37 2.23 ± 1.48 I vs III: 0.000
I vsII: 0.000
Number of D 9-11follicles more than 12 mm 1.13 ± 0.73 2.09 ± 1.00 2.29 ± 1.35 I vs III: 0.005
I vsII: 0.000
Number of mature follicles (≥15 mm) at the Day of hCG 1.20 ± 0.48 1.84 ± 0.92 2.12 ± 0.99 I vs III: 0.000
I vsII: 0.000
Table 4 Endometrial thickness (cm) in study groups
Group I Group II Group III
Cycle day 3 0.14 ± 0.26 0.10 ± 0.23 0.15 ± 0.24
Cycle day 7 0.55 ± 0.26 0.56 ± 0.19 0.50 ± 0.19
Cycle day 9-11 0.65 ± 0.18 0.77 ± 0.96 0.62 ± 0.16
Day of hCG injection 0.86 ± 0.16 0.82 ± 0.14 0.86 ± 0.23
P value non-significant when comparing group I to either group II or III.
Table 5 Pregnancy rate in study groups
Group I
Number (%)
Combined groups II, III
Number (%)
P
value
Pregnancy rate/cycle
started
3/71 (4.2) 22/229 (9.61) 0.02
Pregnancy rate/cycle
completed
3/63 (4.8) 22/185 (11.89) 0.02
Cumulative
pregnancy rate
3/47 (6.4) 22/161 (13.7) 0.01
Twin pregnancy 0/3 (0) 3/22 (13.6) 0.01
Miscarriage (No) 0/3 (0) 3/22 (13.6) 0.01
Bedaiwy et al. Reproductive Biology and Endocrinology 2011, 9:83
http://www.rbej.com/content/9/1/83
Page 4 of 6administration to all women undergoing IUI so that
timing of insemination can be optimized. The women
undergoing natural cycle monitoring usually requested
everything to be natural including no hCG trigger so
t h ed i f f e r e n c eb e t w e e nt h eg r o u p si su n l i k e l yt ob e
related to the letrozole. Spontaneous LH surges do
occur with letrozole for ovulation induction.
This study has some limitations, the most important
of which include that it is retrospective, non-powered,
non-randomized and not blinded. These issues are
inherent in retrospective studies. However, we believe
the results are of interest since there are few studies
comparing natural cycles to letrozole-stimulated cycles.
The main distinguishing features of letrozole as an ovu-
lation inducing agent is its endometrial sparing effect
and the early cycle multi-follicular development that
m a yh a v et r a n s l a t e di n t oab e t t e rp r e g n a n c yr a t ei nt h e
present study. In addition, a recent study demonstrated
that letrozole improves blood flow compared to CC and
this observation may also be associated with improved
pregnancy rates [19]. A well-designed and powered ran-
domized clinical trial will be needed to confirm this
result.
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